Satoshi Ichiyama
Kyoto University
14 Papers
27 Citations
Satoshi Ichiyama is an academic researcher from Kyoto University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 14 publications.
Chat about Author
Papers
Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum-β-lactamase-producing Escherichia coli in Japan
Yasufumi Matsumura,Masaki Yamamoto,Miki Nagao,Gou Hotta,Aki Matsushima,Yutaka Ito,Shunji Takakura,Satoshi Ichiyama +7 more
TL;DR: The B 2-ST131-O25b, B2-ST 131-O16 and D-ST405 clonal groups have contributed to the spread of ESBL-producing E. coli in Japan.
Regional spread and control of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Kyoto, Japan
Aki Matsushima,S. Takakura,Masaki Yamamoto,Yasufumi Matsumura,Michinori Shirano,Miki Nagao,Yutaka Ito,Yoshitsugu Iinuma,T. Shimizu,Naohisa Fujita,Satoshi Ichiyama +10 more
TL;DR: While VRE did spread within the Kyoto region, the VRE control programme succeeded in controlling the overall VRE spread.
36
Molecular and clinical characterization of plasmid‐mediated AmpC β‐lactamase‐producing Escherichia coli bacteraemia: a comparison with extended‐spectrum β‐lactamase‐producing and non‐resistant E. coli bacteraemia
Yasufumi Matsumura,Miki Nagao,Mitsutaka Iguchi,Tetsuya Yagi,Toshiaki Komori,Naohisa Fujita,Masaki Yamamoto,Aki Matsushima,S. Takakura,Satoshi Ichiyama +9 more
TL;DR: Previous isolation of multidrug-resistant bacteria and intravascular catheterization were independently associated with a lower risk for AmpC-E, and the spread of the O25b-ST131-B2 clone between ESBL-E and NR-E was not dominated by any specific clone.
21
Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer.
Yuichi Sakamori,Katsuhiro Masago,Katsuyuki Ohmori,Yosuke Togashi,Hiroki Nagai,Chiyuki Okuda,Young Hak Kim,Satoshi Ichiyama,Michiaki Mishima +8 more
TL;DR: Findings indicate that the late release of CEPs is a common phenomenon after chemotherapeutic treatment, and the correlation with clinical response to chemotherapy provides further support for the biologic relevance of these cells in patients' prognosis and highlights the potential use of Ceps as therapeutic targets.
Cefotaxime for the detection of extended-spectrum β-lactamase or plasmid-mediated AmpC β-lactamase and clinical characteristics of cefotaxime-non-susceptible Escherichia coli and Klebsiella pneumoniae bacteraemia
Yasufumi Matsumura,Masaki Yamamoto,Aki Matsushima,Miki Nagao,Yutaka Ito,S. Takakura,Satoshi Ichiyama +6 more
TL;DR: Using the current breakpoints of the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST), cefotaxime alone can identify ESBL or pAmpC producers.